Physician profile
Kevin M Grant
NPI 1043487929
$4,013.23
in general payments reported to CMS, 2019-2025
17 companies · $617 in 2025
The $617 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $201 · 2021: $1,088 · 2022: $558 · 2023: $923 · 2024: $428 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743 · Entertainment: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.31 |
| Entertainment | $225.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $733.07 | 2020-2025 | Acuvue |
| Coopervision INC. | $620.06 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Optos, INC. | $469.47 | 2020-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sight Sciences, INC. | $377.49 | 2020-2025 | Tearcare System |
| Visioneering Technologies, INC. | $262.97 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $201.30 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $192.69 | 2022-2024 | Alden Scleral Zenlens, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $181.59 | 2019-2021 | |
| Allergan, INC. | $179.92 | 2021-2022 | |
| Biotissue Holdings INC. | $170.84 | 2020-2025 | |
| Abbvie INC. | $158.77 | 2022-2023 | |
| Abb Con-Cise Optical Group LLC | $142.35 | 2021-2023 | Contact Lens, Spectacle Lenses |
| Dompe US, INC. | $117.86 | 2021 | |
| Alcon Vision LLC | $110.74 | 2019-2025 | Tryptyr |
| Optovue, INC. | $35.71 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis, INC | $33.58 | 2021 | |
| Maculogix, INC. | $24.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.